10-Q · August 14, 2026
Replimune’s quarterly loss and EPS improved versus both the preceding quarter and the prior-year period, but the filing extract does not provide total revenue, margins, or segment results and the company has not…
Earnings analysis · 10-Q
REPL earnings analysis
Filed October 28, 2026 · Our reading of the company's report
The latest report
Replimune reported a $(0.54) quarterly EPS result versus the $(0.77) consensus estimate, while revenue and margin metrics were not disclosed. Liquidity was $307.8 million at September 30, 2026, supplemented by $141.0…
Read full summary
Replimune reported a $(0.54) quarterly EPS result versus the $(0.77) consensus estimate, while revenue and margin metrics were not disclosed. Liquidity was $307.8 million at September 30, 2026, supplemented by $141.0 million of August offering proceeds, and the six-month net loss narrowed to $126.9 million from $169.8 million. The outlook remains balanced: FDA approval and initial commercialization of TUDRIQEV are positive, but approval is accelerated and contingent on confirmatory clinical benefit, while the company remains loss-making and expects to require additional financing.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.54
What stood out
-
EPS beat; revenue not disclosed
Reported EPS was $(0.54), ahead of the $(0.77) consensus estimate cited in the accompanying earnings materials. Revenue was not disclosed.
-
TUDRIQEV received FDA approval
The company received FDA approval in August 2026 to commercialize TUDRIQEV with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1 regimen.
-
Liquidity supports more than 12 months
Management reported $307.8 million of cash and cash equivalents at September 30, 2026, and stated that existing liquidity should fund operations and capital expenditures for greater than 12 months.
-
Six-month net loss narrowed
Six-month net loss improved to $126.9 million from $169.8 million in the comparable 2025 period, a reduction of $42.9 million, or approximately 25.3%.
-
Equity financing bolstered cash
The August 2026 equity offering generated $141.0 million of net proceeds, increasing liquidity ahead of the TUDRIQEV launch and confirmatory-trial requirements.
-
SEC investigation closed without action
The SEC concluded its investigation on June 24, 2026 and was not recommending an enforcement action, although related shareholder litigation remains outstanding.
What to watch
-
Accelerated-approval withdrawal risk
TUDRIQEV was approved under accelerated approval, and continued approval depends on verification of clinical benefit in one or more confirmatory trials, including IGNYTE-3. Failure to confirm benefit could result in FDA withdrawal of approval.
-
Single-product commercialization risk
The company states that its near-term prospects are wholly dependent on TUDRIQEV, its only FDA-approved product. Commercialization began in early October 2026, leaving limited operating history for assessing product demand and market acceptance.
-
Continued losses and financing need
The company reported a $126.9 million net loss for the six months ended September 30, 2026 and an accumulated deficit of $1,389.4 million. Management also states that additional financing will be required, creating dilution and financing-availability risk.
-
Regulatory litigation exposure
The company received a second CRL for the RP1 BLA in April 2026 and faces related securities litigation, including a second amended complaint filed after the second CRL and a separate complaint filed on August 6, 2026.
-
Commercial infrastructure rebuild
Commercial execution risk increased after significant reductions in the in-house sales, marketing and commercialization teams following the April 2026 CRL; the company states it is rebuilding those capabilities for launch.
-
Manufacturing and supply-chain risk
The company has one in-house manufacturing site, an approximately 63,000-square-foot Framingham facility, while also relying on third-party manufacturers and suppliers. Manufacturing qualification, supply interruptions or quality failures could delay clinical or commercial supply.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that cash and cash equivalents, including $141.0 million of net proceeds from the August 2026 offering, are expected to fund operations and capital expenditures for greater than 12 months from issuance of the financial statements.
Earlier filings 4
10-K · June 29, 2026
Replimune Group, Inc.'s 2026 10-K reveals a challenging year marked by a continuing net loss of $313.9 million, an operational cash burn that necessitates urgent funding, and no revenue generated to date as the company…
10-Q · February 8, 2024
Replimune reported a Q3 net loss of $51.1 million (EPS -$0.77) versus a loss of $39.7 million (EPS -$0.69) in the prior-year quarter, driven by higher R&D and SG&A spend. Cash and short-term investments totaled $97,672…
10-Q · August 3, 2023
Replimune reported a Q1 net loss of $49.6M ($0.75 per share), modestly better than the prior-year quarter loss per share of $0.78. Operating expenses rose meaningfully as R&D increased to $40.4M and SG&A to $15.2M,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.